Sunesis Pharmaceuticals Inc (SNSS) Discloses Form 4 Insider Buying : Exec. Daniel N Jr Swisher Buys 25,000 Shares
By David Egan -
Sep 3, 2015
Sunesis Pharmaceuticals Inc (SNSS) Discloses Insider Transaction. Daniel N Jr Swisher , CEO of Sunesis Pharmaceuticals Inc purchased 25,000 shares on Aug 24, 2015. The Insider buying transaction was disclosed on Aug 26, 2015 to the Securities and Exchange Commission. The shares were purchased at $1.01 per share for a total value of $25,250.00.
The company shares have dropped 83.78% in the past 52 Weeks. On September 29, 2014 The shares registered one year high of $7.78 and one year low was seen on July 27, 2015 at $0.84. The 50-day moving average is $1.83 and the 200 day moving average is recorded at $2.34. S&P 500 has rallied 0.67% during the last 52-weeks. Currently the company Insiders own 0.5% of Sunesis Pharmaceuticals, Inc. Company shares. In the past six months, there is a change of -61.83% in the total insider ownership. Institutional Investors own 69.1% of Company shares. During last 3 month period, -2.42% of total institutional ownership has changed in the company shares.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) stock has received a short term price target of $ 1.9 from 5 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $0.74. The higher estimate of target price is $3 , while the lower price target estimate is $1 Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) ended Monday session in red amid volatile trading. The shares closed down 0.02 points or 1.65% at $1.19 with 743,990 shares getting traded. Post opening the session at $1.24, the shares hit an intraday low of $1.18 and an intraday high of $1.29 and the price vacillated in this range throughout the day. The company has a market cap of $90 million and the number of outstanding shares have been calculated to be 75,471,000 shares. The 52-week high of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) is $7.78 and the 52-week low is $0.84.
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Company’s VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Company’s Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
